125 related articles for article (PubMed ID: 38008257)
1. Lymph Node Ratio as a Predictive Factor of Persistent/Recurrent Disease in Patients With Medullary Thyroid Cancer: A Single-Center Retrospective Study.
Prinzi A; Frasca F; Russo M; Le Moli R; Belfiore A; Malandrino P
Endocr Pract; 2024 Mar; 30(3):194-199. PubMed ID: 38008257
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value of lymph node ratio in Medullary thyroid carcinoma: A multi-center study.
Rozenblat T; Hirsch D; Robenshtok E; Grozinsky-Glasberg S; Gross DJ; Mazeh H; Benbassat C; Twito O; Levy S; Mizrachi A; Shpitzer T; Bachar G
Eur J Surg Oncol; 2020 Nov; 46(11):2023-2028. PubMed ID: 32389525
[TBL] [Abstract][Full Text] [Related]
3. Optimal value of lymph node ratio and metastatic lymph node size to predict risk of recurrence in pediatric thyroid cancer with lateral neck metastasis.
Back K; Kim TH; Lee J; Kim JS; Choe JH; Oh YL; Cho A; Kim JH
J Pediatr Surg; 2023 Mar; 58(3):568-573. PubMed ID: 35973863
[TBL] [Abstract][Full Text] [Related]
4. Lymph node ratio in lateral neck is an independent risk factor for recurrence-free survival in papillary thyroid cancer patients with positive lymph nodes.
Luo Z; Hei H; Qin J; Zheng C; Gong W
Endocrine; 2022 Dec; 78(3):484-490. PubMed ID: 36018538
[TBL] [Abstract][Full Text] [Related]
5. Pre-ablation stimulated thyroglobulin is a better predictor of recurrence in pathological N1a papillary thyroid carcinoma than the lymph node ratio.
Chang YW; Kim HS; Jung SP; Kim HY; Lee JB; Bae JW; Son GS
Int J Clin Oncol; 2016 Oct; 21(5):862-868. PubMed ID: 26837274
[TBL] [Abstract][Full Text] [Related]
6. Value of lymph node ratio as a prognostic factor of recurrence in medullary thyroid cancer.
Hao W; Zhao J; Guo F; Gu P; Zhang J; Huang D; Ruan X; Zeng Y; Zheng X; Gao M
PeerJ; 2023; 11():e15025. PubMed ID: 36935920
[TBL] [Abstract][Full Text] [Related]
7. Surgical strategy for the treatment of sporadic medullary thyroid carcinoma: our experience.
Lupone G; Antonino A; Rosato A; Zenone P; Iervolino EM; Grillo M; De Palma M
G Chir; 2012; 33(11-12):395-9. PubMed ID: 23140924
[TBL] [Abstract][Full Text] [Related]
8. Prognostic implications of lymph node yield and lymph node ratio in papillary thyroid carcinoma.
Vas Nunes JH; Clark JR; Gao K; Chua E; Campbell P; Niles N; Gargya A; Elliott MS
Thyroid; 2013 Jul; 23(7):811-6. PubMed ID: 23373961
[TBL] [Abstract][Full Text] [Related]
9. Optimal Cut-Off Values of Lymph Node Ratio Predicting Recurrence in Papillary Thyroid Cancer.
Lee SG; Ho J; Choi JB; Kim TH; Kim MJ; Ban EJ; Lee CR; Kang SW; Jeong JJ; Nam KH; Jung SG; Jo YS; Lee J; Chung WY
Medicine (Baltimore); 2016 Feb; 95(5):e2692. PubMed ID: 26844509
[TBL] [Abstract][Full Text] [Related]
10. The prognostic value of lymph node ratio in survival of non-metastatic breast carcinoma patients.
Singh D; Mandal A
Breast Cancer Res Treat; 2020 Dec; 184(3):839-848. PubMed ID: 32852709
[TBL] [Abstract][Full Text] [Related]
11. Metastatic lymph node ratio as an important prognostic factor in advanced gallbladder carcinoma with at least 6 lymph nodes retrieved.
Wang J; Liu F; Ma W; Hu H; Li F
Langenbecks Arch Surg; 2023 Sep; 408(1):382. PubMed ID: 37770780
[TBL] [Abstract][Full Text] [Related]
12. Lymph node ratio as a tool to stratify patients with N1b papillary thyroid cancer.
Luo Z; Hei H; Qin J; Zheng C; Gong W; Zhou B
Langenbecks Arch Surg; 2023 Aug; 408(1):315. PubMed ID: 37584830
[TBL] [Abstract][Full Text] [Related]
13. [Impact of regional positive lymph node ratio of gallbladder carcinoma on prognosis].
Zhou YM; Mi HC; Jiang W; Jiang Y; Hua YF; Lu CJ; Wang CN; Lu CD
Zhonghua Zhong Liu Za Zhi; 2022 Nov; 44(11):1202-1207. PubMed ID: 36380669
[No Abstract] [Full Text] [Related]
14. Lymph node ratio predicts recurrence in papillary thyroid cancer.
Schneider DF; Mazeh H; Chen H; Sippel RS
Oncologist; 2013; 18(2):157-62. PubMed ID: 23345543
[TBL] [Abstract][Full Text] [Related]
15. A proposed grading scheme for predicting recurrence in medullary thyroid cancer based on the Ki67 index and metastatic lymph node ratio.
Xu P; Wu D; Liu X
Endocrine; 2023 Jul; 81(1):107-115. PubMed ID: 36823341
[TBL] [Abstract][Full Text] [Related]
16. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems.
Kebebew E; Ituarte PH; Siperstein AE; Duh QY; Clark OH
Cancer; 2000 Mar; 88(5):1139-48. PubMed ID: 10699905
[TBL] [Abstract][Full Text] [Related]
17. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines.
Mitchell AL; Gandhi A; Scott-Coombes D; Perros P
J Laryngol Otol; 2016 May; 130(S2):S150-S160. PubMed ID: 27841128
[TBL] [Abstract][Full Text] [Related]
18. Predictive Value of the Number of Harvested Lymph Nodes and Cut-Off for Lymph Node Ratio in the Prognosis of Stage II and III Colorectal Cancer Patients.
Li Destri G; Barchitta M; Pesce A; Latteri S; Bosco D; Di Cataldo A; Agodi A; Puleo S
J Invest Surg; 2019 Jan; 32(1):1-7. PubMed ID: 28972442
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of lymph node ratio in patients with squamous cell carcinoma of the floor of the mouth.
Liu XC; Ma SR; Shi S; Zhao YF; Jia J
Int J Oral Maxillofac Surg; 2022 Mar; 51(3):307-313. PubMed ID: 34281747
[TBL] [Abstract][Full Text] [Related]
20. Time Kinetics and prognosis roles of calcitonin after surgery for medullary thyroid carcinoma.
Guo F; Fu G; Li F; Hua Y; Wang Z; Zheng X; Zhao J; Gao M
World J Surg Oncol; 2024 May; 22(1):121. PubMed ID: 38711029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
